Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 66(12): 8140-8158, 2023 06 22.
Artículo en Inglés | MEDLINE | ID: mdl-37279401

RESUMEN

In the eye, the isomerization of all-trans-retinal to 11-cis-retinal is accomplished by a metabolic pathway termed the visual cycle that is critical for vision. RPE65 is the essential trans-cis isomerase of this pathway. Emixustat, a retinoid-mimetic RPE65 inhibitor, was developed as a therapeutic visual cycle modulator and used for the treatment of retinopathies. However, pharmacokinetic liabilities limit its further development including: (1) metabolic deamination of the γ-amino-α-aryl alcohol, which mediates targeted RPE65 inhibition, and (2) unwanted long-lasting RPE65 inhibition. We sought to address these issues by more broadly defining the structure-activity relationships of the RPE65 recognition motif via the synthesis of a family of novel derivatives, which were tested in vitro and in vivo for RPE65 inhibition. We identified a potent secondary amine derivative with resistance to deamination and preserved RPE65 inhibitory activity. Our data provide insights into activity-preserving modifications of the emixustat molecule that can be employed to tune its pharmacological properties.


Asunto(s)
Propanolaminas , Retinoides , Retinoides/farmacología , Retinoides/metabolismo , Éteres Fenílicos/farmacología , Visión Ocular , Retinaldehído/metabolismo , Proteínas del Ojo
2.
J Med Chem ; 64(12): 8287-8302, 2021 06 24.
Artículo en Inglés | MEDLINE | ID: mdl-34081480

RESUMEN

Recycling of all-trans-retinal to 11-cis-retinal through the visual cycle is a fundamental metabolic pathway in the eye. A potent retinoid isomerase (RPE65) inhibitor, (R)-emixustat, has been developed and tested in several clinical trials; however, it has not received regulatory approval for use in any specific retinopathy. Rapid clearance of this drug presents challenges to maintaining concentrations in eyes within a therapeutic window. To address this pharmacokinetic inadequacy, we rationally designed and synthesized a series of emixustat derivatives with strategically placed fluorine and deuterium atoms to slow down the key metabolic transformations known for emixustat. Crystal structures and quantum chemical analysis of RPE65 in complex with the most potent emixustat derivatives revealed the structural and electronic bases for how fluoro substituents can be favorably accommodated within the active site pocket of RPE65. We found a close (∼3.0 Å) F-π interaction that is predicted to contribute ∼2.4 kcal/mol to the overall binding energy.


Asunto(s)
Ojo/metabolismo , Éteres Fenílicos/farmacocinética , Propanolaminas/farmacocinética , Amina Oxidasa (conteniendo Cobre)/metabolismo , Animales , Bovinos , Moléculas de Adhesión Celular/metabolismo , Cristalografía por Rayos X , Deuterio/química , Diseño de Fármacos , Flúor/química , Halogenación , Ratones , Estructura Molecular , Éteres Fenílicos/síntesis química , Éteres Fenílicos/metabolismo , Propanolaminas/síntesis química , Propanolaminas/metabolismo , Unión Proteica , Relación Estructura-Actividad , cis-trans-Isomerasas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...